---
figid: PMC8200410__fnut-08-682243-g0006
figtitle: 'Ketogenic Metabolic Therapy, Without Chemo or Radiation, for the Long-Term
  Management of IDH1-Mutant Glioblastoma: An 80-Month Follow-Up Case Report'
organisms:
- NA
pmcid: PMC8200410
filename: fnut-08-682243-g0006.jpg
figlink: /pmc/articles/PMC8200410/figure/F6/
number: F6
caption: KMT/IDH1 synergistic interaction for targeting GBM energy metabolism. KMT
  can reduce glucose availability for glycolysis while also interfering with the glutaminolysis
  pathway. Glutamine-driven mitochondrial substrate-level phosphorylation (mSLP),
  in the glutaminolysis pathway, is a major source of ATP synthesis for GBM cells
  (, ). The glutaminolysis pathway (red) becomes dominant in tumor cells with inefficient
  OxPhos and that express the dimeric PKM2 isoform. PKM2 is expressed in GBM and produces
  less ATP through glycolysis than does the PKM1 isoform (–). The elevation of ketone
  bodies (β-hydroxybutyrate and acetoacetate) through KMT could indirectly reduce
  ATP synthesis through the succinate CoA ligase (SUCL) reaction by diverting CoA
  from succinate to acetoacetate. The IDH1 mutation could further reduce ATP synthesis
  through mSLP by increasing synthesis of 2-hydroxyglutarate from α-ketoglutarate
  and thus reducing the succinyl CoA substrate for the SUCL reaction (, ). Besides
  its potential effect in reducing glutaminolysis, 2-hydroxyglutarate can also target
  multiple HIF1α-responsive genes and enzymes in the glycolysis pathway thus limiting
  synthesis of metabolites and one-carbon metabolism needed for rapid tumor growth
  (, , , ). The down-regulation of Hif1-α-regulated lactate dehydrogenase A (LDHA),
  through the action of both KMT and the IDH1 mutation, would reduce extracellular
  lactate levels thus reducing microenvironment inflammation and tumor cell invasion.
  Hence, the simultaneous inhibition of glycolysis and glutaminolysis through the
  synergistic effects of KMT and the IDH1 mutation will stress the majority of signaling
  pathways necessary for rapid GBM growth. BDH, β-hydroxybutyrate dehydrogenase; FAD,
  flavin adenine dinucleotide; GLSc, glutaminase, cytosolic; GLSm, glutaminase; mitochondrial;
  GLUD, glutamate dehydrogenase; GOT2, aspartate aminotransferase; KGDHC, α-ketoglutarate
  dehydrogenase complex; LDHA, lactate dehydrogenase A; NME, nucleoside diphosphate
  kinase; OXCT1, succinyl-CoA:3-ketoacid coenzyme A transferase 1; PC, pyruvate carboxylase;
  PDH, pyruvate dehydrogenase; PEP, phosphoenolpyruvate; PKM2, pyruvate kinase M2;
  SDH, succinate dehydrogenase; SUCL, succinate-CoA ligase. Reprinted with modifications
  from Seyfried et al. ().
papertitle: 'Ketogenic Metabolic Therapy, Without Chemo or Radiation, for the Long-Term
  Management of IDH1-Mutant Glioblastoma: An 80-Month Follow-Up Case Report.'
reftext: Thomas N. Seyfried, et al. Front Nutr. 2021;8:682243.
year: '2021'
doi: 10.3389/fnut.2021.682243
journal_title: Frontiers in Nutrition
journal_nlm_ta: Front Nutr
publisher_name: Frontiers Media S.A.
keywords: standard of care | glycolysis | glutaminolysis | fasting | mitochondrial
  substrate level phosphorylation (mSLP) | 2-hydroxyglutarate | carnivore diet
automl_pathway: 0.9503078
figid_alias: PMC8200410__F6
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC8200410__F6
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8200410__fnut-08-682243-g0006.html
  '@type': Dataset
  description: KMT/IDH1 synergistic interaction for targeting GBM energy metabolism.
    KMT can reduce glucose availability for glycolysis while also interfering with
    the glutaminolysis pathway. Glutamine-driven mitochondrial substrate-level phosphorylation
    (mSLP), in the glutaminolysis pathway, is a major source of ATP synthesis for
    GBM cells (, ). The glutaminolysis pathway (red) becomes dominant in tumor cells
    with inefficient OxPhos and that express the dimeric PKM2 isoform. PKM2 is expressed
    in GBM and produces less ATP through glycolysis than does the PKM1 isoform (–).
    The elevation of ketone bodies (β-hydroxybutyrate and acetoacetate) through KMT
    could indirectly reduce ATP synthesis through the succinate CoA ligase (SUCL)
    reaction by diverting CoA from succinate to acetoacetate. The IDH1 mutation could
    further reduce ATP synthesis through mSLP by increasing synthesis of 2-hydroxyglutarate
    from α-ketoglutarate and thus reducing the succinyl CoA substrate for the SUCL
    reaction (, ). Besides its potential effect in reducing glutaminolysis, 2-hydroxyglutarate
    can also target multiple HIF1α-responsive genes and enzymes in the glycolysis
    pathway thus limiting synthesis of metabolites and one-carbon metabolism needed
    for rapid tumor growth (, , , ). The down-regulation of Hif1-α-regulated lactate
    dehydrogenase A (LDHA), through the action of both KMT and the IDH1 mutation,
    would reduce extracellular lactate levels thus reducing microenvironment inflammation
    and tumor cell invasion. Hence, the simultaneous inhibition of glycolysis and
    glutaminolysis through the synergistic effects of KMT and the IDH1 mutation will
    stress the majority of signaling pathways necessary for rapid GBM growth. BDH,
    β-hydroxybutyrate dehydrogenase; FAD, flavin adenine dinucleotide; GLSc, glutaminase,
    cytosolic; GLSm, glutaminase; mitochondrial; GLUD, glutamate dehydrogenase; GOT2,
    aspartate aminotransferase; KGDHC, α-ketoglutarate dehydrogenase complex; LDHA,
    lactate dehydrogenase A; NME, nucleoside diphosphate kinase; OXCT1, succinyl-CoA:3-ketoacid
    coenzyme A transferase 1; PC, pyruvate carboxylase; PDH, pyruvate dehydrogenase;
    PEP, phosphoenolpyruvate; PKM2, pyruvate kinase M2; SDH, succinate dehydrogenase;
    SUCL, succinate-CoA ligase. Reprinted with modifications from Seyfried et al.
    ().
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - LKRSDH
  - SdhB
  - SdhA
  - Sodh-2
  - SdhC
  - Desat2
  - Fadd
  - Fad2
  - Desat1
  - Fancd2
  - ATPsynbeta
  - Atpalpha
  - adp
  - amon
  - pi
  - Pep
  - bgcn
  - tgo
  - sima
  - Idh
  - Idh3b
  - ha
  - ld
  - Gdh
  - Got2
  - Got1
  - ROS1
  - SARDH
  - SDHB
  - SORD
  - SDS
  - MTG1
  - BRCA2
  - FANCD2
  - PSEN1
  - ATP8A2
  - WDTC1
  - CAMKMT
  - ASH1L
  - DOT1L
  - EHMT1
  - EHMT2
  - EZH1
  - EZH2
  - KMT2A
  - KMT2B
  - KMT2C
  - KMT2D
  - KMT2E
  - KMT5A
  - KMT5B
  - KMT5C
  - MECOM
  - NSD1
  - NSD2
  - NSD3
  - PRDM16
  - PRDM2
  - PRDM6
  - PRDM8
  - PRDM9
  - SETD1A
  - SETD1B
  - SETD2
  - SETD7
  - SETDB1
  - SETDB2
  - SMYD1
  - SMYD2
  - SMYD3
  - SUV39H1
  - SUV39H2
  - OXCT1
  - PAEP
  - PREP
  - PTPN22
  - BDH1
  - HIF1A
  - ARNT
  - PKM
  - PKLR
  - IDH1
  - IDH2
  - LDHA
  - GLUD1
  - GOT2
  - DECR1
---
